Oncobiologics Inc (ONS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oncobiologics Inc (ONS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8222
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncobiologics Inc (Oncobiologics) is a clinical stage biopharmaceutical company that identifies, develops, manufactures and commercializes biosimilar therapeutics in the areas of immunology and oncology. The company’s pipeline products include ONS-3010, an adalimumab biosimilar intended for rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease and ulcerative colitis; and ONS-1045, a bevacizumab (Avastin) biosimilar intended to treat non-squamous non-small cell lung cancer. The company also develops various preclinical biosimilar product candidates including ONS-1050, a trastuzumab biosimilar that interferes with human epidermal growth factor receptor 2; ONS-4010, a biosimilar to denosumab; and ONS-3040, a biosimilar to ustekinumab. It develops products through strategic collaborations and partnerships with biotechnology and pharmaceutical companies. Oncobiologics is headquartered in Cranbury, New Jersey, the US.

Oncobiologics Inc (ONS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Oncobiologics Raises Additional USD13 Million in Venture Financing 12
Oncobiologics Raises USD31 Million in Financing Round 13
Partnerships 14
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14
Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18
Licensing Agreements 19
Oncobiologics Enters into Licensing Agreement with GMS Tenshi 19
Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 20
Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21
Ipca Labs Amends Licensing Agreement with Oncobiologics 22
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 23
Equity Offering 24
Oncobiologics Raises USD7.5 Million in Second Tranche of Private Placement of Shares and Warrants 24
Oncobiologics Raises USD7.5 Million in First Tranche of Private Placement of Shares and Warrants 25
Oncobiologics Plans to Raise Funds through Public Offering of Shares 26
Oncobiologics Raises USD25 Million in Private Placement of Preferred Shares and Warrants 27
Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 30
Oncobiologics Raises USD35 Million in IPO of Units 31
Oncobiologics to Raise USD5 Million in Private Placement of Units 33
Oncobiologics Raises USD4 Million in Private Placement of Shares 34
Oncobiologics Raises USD7 Million in Private Placement of Shares 35
Debt Offering 36
Oncobiologics Raises USD1.5 Million in Third and Final Tranche of Private Placement of Notes and Warrants Due 2017 36
Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 37
Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 38
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 39
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 40
Oncobiologics Inc – Key Competitors 41
Oncobiologics Inc – Key Employees 42
Oncobiologics Inc – Locations And Subsidiaries 43
Head Office 43
Recent Developments 44
Financial Announcements 44
Aug 14, 2018: Oncobiologics povides business update and reports third quarter financial results for fiscal 2018 44
May 15, 2018: Oncobiologics Announces Second Quarter Financial Results for Fiscal 2018 45
Feb 14, 2018: Oncobiologics Reports Q1 Fiscal 2018 Financial Results 46
Corporate Communications 49
Aug 02, 2018: Oncobiologics appoints Lawrence A. Kenyon as president and CEO 49
Jul 11, 2018: Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements 50
Apr 17, 2018: Oncobiologics Appoints Randy Thurman To Board Of Directors 51
Mar 27, 2018: Oncobiologics Names Dr. Joerg Windisch As Board Director 52
Feb 13, 2018: Oncobiologics Receives Positive Nasdaq Listing Determination 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Oncobiologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oncobiologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oncobiologics Raises Additional USD13 Million in Venture Financing 12
Oncobiologics Raises USD31 Million in Financing Round 13
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14
Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18
Oncobiologics Enters into Licensing Agreement with GMS Tenshi 19
Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 20
Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21
Ipca Labs Amends Licensing Agreement with Oncobiologics 22
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 23
Oncobiologics Raises USD7.5 Million in Second Tranche of Private Placement of Shares and Warrants 24
Oncobiologics Raises USD7.5 Million in First Tranche of Private Placement of Shares and Warrants 25
Oncobiologics Plans to Raise Funds through Public Offering of Shares 26
Oncobiologics Raises USD25 Million in Private Placement of Preferred Shares and Warrants 27
Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 30
Oncobiologics Raises USD35 Million in IPO of Units 31
Oncobiologics to Raise USD5 Million in Private Placement of Units 33
Oncobiologics Raises USD4 Million in Private Placement of Shares 34
Oncobiologics Raises USD7 Million in Private Placement of Shares 35
Oncobiologics Raises USD1.5 Million in Third and Final Tranche of Private Placement of Notes and Warrants Due 2017 36
Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 37
Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 38
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 39
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 40
Oncobiologics Inc, Key Competitors 41
Oncobiologics Inc, Key Employees 42

List of Figures
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Oncobiologics Inc (ONS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Independent Electricity System Operator:企業の戦略的SWOT分析
    Independent Electricity System Operator - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Petroleos de Venezuela SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Petroleos de Venezuela SA (PDVSA) is a state-owned oil and gas company. It plans, coordinates, supervises, and controls the activities in the entire oil and gas value chain. The company explores for and develops oil and other hydrocarbons; refines, trades, and supplies that in domestic and o …
  • Glaukos Corp (GKOS):企業の製品パイプライン分析2018
    Summary Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such …
  • The Bank of Nova Scotia:企業のM&A・事業提携・投資動向
    The Bank of Nova Scotia - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Bank of Nova Scotia Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • The Blackstone Group LP:企業の戦略・SWOT・財務情報
    The Blackstone Group LP - Strategy, SWOT and Corporate Finance Report Summary The Blackstone Group LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • National Central Cooling Company:企業の戦略・SWOT・財務情報
    National Central Cooling Company - Strategy, SWOT and Corporate Finance Report Summary National Central Cooling Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Mechanical Technology Inc (MKTY):企業の財務・戦略的SWOT分析
    Summary Mechanical Technology Inc (MTI) is an electronic equipment company that designs, manufactures, and sells test and measurement instruments and systems. The company offers tools, systems and solutions for markets and applications that require precise measurements and control of products, proce …
  • GS Energy Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary GS Energy Corp (GS Energy) is an energy holding company that manufactures and markets transportation fuels. The company's services include exploration and production, green growth, gas and electric power, refining and petrochemicals. It's refining and petrochemicals services comprise manufac …
  • Santander UK PLC:企業の戦略・SWOT・財務分析
    Santander UK PLC - Strategy, SWOT and Corporate Finance Report Summary Santander UK PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • National Fuel Gas Co (NFG):企業の財務・戦略的SWOT分析
    National Fuel Gas Co (NFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • CellSeed Inc (7776):企業の製品パイプライン分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …
  • TRPHARM Ilac Sanayi Tic AS:製薬・医療:M&Aディール及び事業提携情報
    Summary TRPHARM Ilac Sanayi Tic AS (TRPharm) is a biopharmaceutical company focused on development and commercialization of novel innovative medicines for the treatment of oncology, neurology, inflammatory and rare diseases. The company conducts research and development programs and provide treatmen …
  • Aratana Therapeutics Inc (PETX):製薬・医療:M&Aディール及び事業提携情報
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • World Fuel Services Corporation:企業の戦略・SWOT・財務情報
    World Fuel Services Corporation - Strategy, SWOT and Corporate Finance Report Summary World Fuel Services Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Magnotta Winery Corporation:企業の戦略・SWOT・財務分析
    Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report Summary Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Shenzhen Moso Power Supply Technology Co Ltd (002660):電力:M&Aディール及び事業提携情報
    Summary Shenzhen Moso Power Supply Technology Co Ltd (Moso Power) is a manufacturer of electronics and electrical appliances. The company designs and distributes consumer electronics and solar photovoltaic products. Its products include LED driver, outdoor lighting, industrial lighting, landscape li …
  • Edison International (EIX):電力:M&Aディール及び事業提携情報
    Summary Edison International (Edison) is an energy holding company. The company generates and distributes electric power; and invests in energy services and technologies, including renewable power, through its subsidiaries. It develops solar products and carries out commercial rooftop installation o …
  • New Jersey Resources Corp (NJR):企業の財務・戦略的SWOT分析
    New Jersey Resources Corp (NJR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Invenergy LLC:企業の戦略的SWOT分析
    Invenergy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Baxter International Inc (BAX):企業の財務・戦略的SWOT分析
    Baxter International Inc (BAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆